OncoMed Pharmaceuticals, Inc. (OMED) Reaches $3.16 After 6.00% Up Move; Shorts at Infusystems Holdings (NYSEAMERICAN:INFU) Lowered By 26.47%

April 21, 2018 - By Peter Erickson

InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) Logo

The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) is a huge mover today! The stock increased 2.60% or $0.08 during the last trading session, reaching $3.16. About 92,476 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 21, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.The move comes after 5 months positive chart setup for the $120.90M company. It was reported on Apr, 21 by Barchart.com. We have $3.35 PT which if reached, will make NASDAQ:OMED worth $7.25M more.

Infusystems Holdings Inc (NYSEAMERICAN:INFU) had a decrease of 26.47% in short interest. INFU’s SI was 12,500 shares in April as released by FINRA. Its down 26.47% from 17,000 shares previously. With 51,700 avg volume, 0 days are for Infusystems Holdings Inc (NYSEAMERICAN:INFU)’s short sellers to cover INFU’s short positions. The stock increased 3.85% or $0.1 during the last trading session, reaching $2.7. About 5,649 shares traded. InfuSystem Holdings Inc. (NYSEAMERICAN:INFU) has risen 18.43% since April 21, 2017 and is uptrending. It has outperformed by 6.88% the S&P500.

Analysts await OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) to report earnings on May, 14. They expect $-0.24 earnings per share, up 60.66% or $0.37 from last year’s $-0.61 per share. After $0.25 actual earnings per share reported by OncoMed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -196.00% negative EPS growth.

Investors sentiment increased to 1.62 in 2017 Q4. Its up 0.91, from 0.71 in 2017Q3. It improved, as 3 investors sold OncoMed Pharmaceuticals, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Gsa Prtn Limited Liability Partnership reported 0% stake. Bluecrest Cap Management reported 0% stake. The Ontario – Canada-based Royal Bancorp Of Canada has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). 6,117 are owned by Morgan Stanley. Fny Managed Accounts Llc reported 500 shares or 0% of all its holdings. Northern Corporation owns 59,017 shares. Spark Invest Management Limited Liability accumulated 0.01% or 55,800 shares. 521,883 were reported by Alyeska Invest Ltd Partnership. Paloma Prtn Mngmt invested in 0% or 32,858 shares. Primecap Mngmt Commerce Ca invested in 0.02% or 5.57 million shares. National Bank Of New York Mellon stated it has 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Bvf Inc Il has 4.27M shares. Savings Bank Of Montreal Can owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 8,000 shares. Virtu Limited Liability Co reported 41,395 shares. Wells Fargo And Mn owns 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 28,686 shares.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $120.90 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. The company was maintained on Wednesday, January 6 by Mizuho. SunTrust maintained the shares of OMED in report on Thursday, March 8 with “Hold” rating. As per Wednesday, August 10, the company rating was maintained by Jefferies. BMO Capital Markets downgraded it to “Market Perform” rating and $6 target in Tuesday, April 11 report. JMP Securities maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $18 target. Mizuho maintained the stock with “Buy” rating in Tuesday, January 26 report. The company was initiated on Tuesday, December 20 by SunTrust. The firm earned “Mkt Perform” rating on Monday, January 25 by Leerink Swann. The rating was initiated by Jefferies with “Buy” on Wednesday, September 9. The firm has “Buy” rating given on Thursday, September 22 by H.C. Wainwright.

Investors sentiment increased to 1.67 in Q4 2017. Its up 1.36, from 0.31 in 2017Q3. It improved, as 3 investors sold InfuSystem Holdings Inc. shares while 3 reduced holdings. 3 funds opened positions while 7 raised stakes. 6.58 million shares or 1.28% less from 6.66 million shares in 2017Q3 were reported. Renaissance Technology Ltd Limited Liability Company reported 0% of its portfolio in InfuSystem Holdings Inc. (NYSEAMERICAN:INFU). Blackrock Incorporated holds 0% or 57,964 shares in its portfolio. California Public Employees Retirement has 23,800 shares. San Francisco Sentry Invest Group (Ca) holds 0% or 200 shares. Finemark Bancorporation And reported 0.03% stake. Spark Mgmt Ltd Company invested 0% in InfuSystem Holdings Inc. (NYSEAMERICAN:INFU). Acadian Asset Limited Liability Corporation has 0% invested in InfuSystem Holdings Inc. (NYSEAMERICAN:INFU). Tower Research Capital (Trc) has invested 0% in InfuSystem Holdings Inc. (NYSEAMERICAN:INFU). 159 are owned by Federated Investors Pa. Weber Alan W invested 0.06% in InfuSystem Holdings Inc. (NYSEAMERICAN:INFU). Rbf Limited reported 0.01% stake. Lsv Asset accumulated 176,267 shares or 0% of the stock. 2.06 million are held by Minerva Advsr Ltd. Ancora Limited holds 196,037 shares or 0.02% of its portfolio. Bridgeway stated it has 521,176 shares or 0.01% of all its holdings.

Since December 12, 2017, it had 2 insider buys, and 0 sales for $196,602 activity. 20,000 shares valued at $48,000 were bought by Meridian OHC Partners – LP on Friday, March 16.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>